CGEM cullinanoncology.com: Enterprise Value to EBITDA Ratio

Cullinan Therapeutics (CGEM) is a leading developer in targeted oncology therapy, creating advanced antibodies for the treatment of solid tumors. The company is building a comprehensive research environment that accelerates the release of specialized drugs. This price chart illustrates the EV/EBITDA ratio, which currently stands at 0.00. The current growth trajectory is based on expanding clinical trials and penetrating the autoimmune pathology segment through global alliances.

CGEM (Cullinan Oncology) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/14/2026

Comprehensive metric breakdowns and analytics for Cullinan Therapeutics, Inc. (CGEM)

- stock price and consensus target price:

Stock Quotes Cullinan Oncology|CGEM - Average Forecast Price

- company stock capitalization data:

Market Valuation Cullinan Oncology|CGEM - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Cullinan Therapeutics|CGEM - Total Net Assets|Market Capitalization to Book Value Ratio cullinanoncology.com|CGEM - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

CGEM - Company Net Income|Projected Future Earnings Cullinan Therapeutics|CGEM - Price to Earnings Multiple|Projected Price to Earnings Cullinan Therapeutics, Inc.|CGEM - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Cullinan Corp|CGEM - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Cullinan Therapeutics|CGEM - Earnings per share for the trailing year|Quarterly EPS earnings growth cullinanoncology.com|CGEM - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Cullinan Therapeutics

- issuer revenue and sales details:

CGEM - Company Sales Revenue|Projected Sales Volume Cullinan Corp|CGEM - P/S Multiple|Price-to-Projected Revenue Ratio Cullinan Therapeutics

Basic company analysis:Cullinan Oncology CGEM

Original product of cullinanoncology.com

For Cullinan Therapeutics (CGEM), which lacks stable revenue due to the specific nature of oncology drug development, the EV/EBITDA calculation becomes a critical sustainability filter. This metric compares the total enterprise value, including debt, with operating profit before depreciation and amortization, revealing the actual value of the generated cash flow. By analyzing the EV/EBITDA ratio chart against historical data, an investor sees the current value of 0.00. Such a high dependence on cash reserves makes this indicator the primary measure of the company's survival.

Competitor analysis

Genmab AS - Enterprise Value to EBITDA Ratio|Exelixis (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (Kymera Therapeutics Inc)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple relaytx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics, Inc. (NRIX)|TYRA (Tyra Biosciences) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VSTM (Verastem Oncology)|Enterprise Value to EBITDA Multiple Monte Rosa Tx|Immuneering Corp - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (pmvpharma.com) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm Therapeutics KPTI|EV/EBITDA Multiple PPCB|Bio Green Med Solution - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|glycomimetics.com - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple